|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LAMTOR1 |
Gene summary for LAMTOR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LAMTOR1 | Gene ID | 55004 |
| Gene name | late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 | |
| Gene Alias | C11orf59 | |
| Cytomap | 11q13.4 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q6IAA8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55004 | LAMTOR1 | GSM4909282 | Human | Breast | IDC | 2.28e-03 | 3.48e-01 | -0.0288 |
| 55004 | LAMTOR1 | GSM4909290 | Human | Breast | IDC | 3.14e-14 | 5.39e-01 | 0.2096 |
| 55004 | LAMTOR1 | GSM4909294 | Human | Breast | IDC | 8.16e-05 | 1.60e-01 | 0.2022 |
| 55004 | LAMTOR1 | GSM4909296 | Human | Breast | IDC | 1.44e-18 | 2.46e-01 | 0.1524 |
| 55004 | LAMTOR1 | GSM4909297 | Human | Breast | IDC | 2.24e-18 | -2.21e-01 | 0.1517 |
| 55004 | LAMTOR1 | GSM4909301 | Human | Breast | IDC | 1.02e-02 | 7.06e-02 | 0.1577 |
| 55004 | LAMTOR1 | GSM4909304 | Human | Breast | IDC | 1.24e-09 | 4.98e-01 | 0.1636 |
| 55004 | LAMTOR1 | GSM4909305 | Human | Breast | IDC | 1.16e-03 | 2.90e-01 | 0.0436 |
| 55004 | LAMTOR1 | GSM4909307 | Human | Breast | IDC | 4.22e-06 | 3.79e-01 | 0.1569 |
| 55004 | LAMTOR1 | GSM4909308 | Human | Breast | IDC | 3.82e-24 | 5.68e-01 | 0.158 |
| 55004 | LAMTOR1 | GSM4909311 | Human | Breast | IDC | 2.42e-35 | -2.77e-01 | 0.1534 |
| 55004 | LAMTOR1 | GSM4909312 | Human | Breast | IDC | 7.15e-19 | 1.16e-01 | 0.1552 |
| 55004 | LAMTOR1 | GSM4909313 | Human | Breast | IDC | 2.85e-05 | 2.46e-01 | 0.0391 |
| 55004 | LAMTOR1 | GSM4909316 | Human | Breast | IDC | 2.46e-07 | 2.54e-01 | 0.21 |
| 55004 | LAMTOR1 | GSM4909319 | Human | Breast | IDC | 7.76e-51 | -6.57e-02 | 0.1563 |
| 55004 | LAMTOR1 | GSM4909320 | Human | Breast | IDC | 9.82e-08 | 1.28e-01 | 0.1575 |
| 55004 | LAMTOR1 | GSM4909321 | Human | Breast | IDC | 3.59e-23 | 1.32e-01 | 0.1559 |
| 55004 | LAMTOR1 | brca2 | Human | Breast | Precancer | 3.20e-07 | 3.74e-01 | -0.024 |
| 55004 | LAMTOR1 | brca3 | Human | Breast | Precancer | 3.67e-02 | 2.72e-01 | -0.0263 |
| 55004 | LAMTOR1 | NCCBC11 | Human | Breast | DCIS | 2.53e-06 | 2.98e-01 | 0.1232 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000155821 | Liver | HCC | regulation of cell growth | 228/7958 | 414/18723 | 1.34e-07 | 2.55e-06 | 228 |
| GO:00550882 | Liver | HCC | lipid homeostasis | 103/7958 | 167/18723 | 4.27e-07 | 7.18e-06 | 103 |
| GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
| GO:00192162 | Liver | HCC | regulation of lipid metabolic process | 181/7958 | 331/18723 | 4.58e-06 | 5.79e-05 | 181 |
| GO:00319291 | Liver | HCC | TOR signaling | 78/7958 | 126/18723 | 8.49e-06 | 9.97e-05 | 78 |
| GO:004311221 | Liver | HCC | receptor metabolic process | 96/7958 | 166/18723 | 4.69e-05 | 4.50e-04 | 96 |
| GO:000110111 | Liver | HCC | response to acid chemical | 79/7958 | 135/18723 | 1.24e-04 | 1.03e-03 | 79 |
| GO:0032006 | Liver | HCC | regulation of TOR signaling | 63/7958 | 104/18723 | 1.50e-04 | 1.20e-03 | 63 |
| GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
| GO:005509221 | Liver | HCC | sterol homeostasis | 59/7958 | 97/18723 | 2.06e-04 | 1.58e-03 | 59 |
| GO:00070401 | Liver | HCC | lysosome organization | 47/7958 | 74/18723 | 2.13e-04 | 1.63e-03 | 47 |
| GO:00801711 | Liver | HCC | lytic vacuole organization | 47/7958 | 74/18723 | 2.13e-04 | 1.63e-03 | 47 |
| GO:004263221 | Liver | HCC | cholesterol homeostasis | 58/7958 | 96/18723 | 2.99e-04 | 2.13e-03 | 58 |
| GO:004320011 | Liver | HCC | response to amino acid | 68/7958 | 116/18723 | 3.31e-04 | 2.33e-03 | 68 |
| GO:0032008 | Liver | HCC | positive regulation of TOR signaling | 31/7958 | 47/18723 | 9.90e-04 | 5.71e-03 | 31 |
| GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
| GO:00353761 | Liver | HCC | sterol import | 9/7958 | 10/18723 | 2.79e-03 | 1.31e-02 | 9 |
| GO:00705081 | Liver | HCC | cholesterol import | 9/7958 | 10/18723 | 2.79e-03 | 1.31e-02 | 9 |
| GO:00303012 | Liver | HCC | cholesterol transport | 65/7958 | 117/18723 | 2.95e-03 | 1.38e-02 | 65 |
| GO:00159182 | Liver | HCC | sterol transport | 71/7958 | 130/18723 | 3.49e-03 | 1.58e-02 | 71 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04150 | Colorectum | MSS | mTOR signaling pathway | 47/1875 | 156/8465 | 1.19e-02 | 3.99e-02 | 2.44e-02 | 47 |
| hsa041501 | Colorectum | MSS | mTOR signaling pathway | 47/1875 | 156/8465 | 1.19e-02 | 3.99e-02 | 2.44e-02 | 47 |
| hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
| hsa0415012 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LAMTOR1 | SNV | Missense_Mutation | c.24N>C | p.Glu8Asp | p.E8D | Q6IAA8 | protein_coding | tolerated(0.53) | benign(0) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| LAMTOR1 | SNV | Missense_Mutation | c.55N>T | p.Arg19Trp | p.R19W | Q6IAA8 | protein_coding | tolerated(0.2) | benign(0.047) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| LAMTOR1 | SNV | Missense_Mutation | rs761347517 | c.271N>T | p.Arg91Cys | p.R91C | Q6IAA8 | protein_coding | tolerated(0.09) | benign(0.018) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LAMTOR1 | insertion | Frame_Shift_Ins | novel | c.86dupC | p.Thr30TyrfsTer20 | p.T30Yfs*20 | Q6IAA8 | protein_coding | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| LAMTOR1 | SNV | Missense_Mutation | c.272N>A | p.Arg91His | p.R91H | Q6IAA8 | protein_coding | tolerated(0.07) | benign(0.018) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LAMTOR1 | SNV | Missense_Mutation | novel | c.98N>C | p.Leu33Pro | p.L33P | Q6IAA8 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LAMTOR1 | SNV | Missense_Mutation | rs370533903 | c.251N>A | p.Arg84His | p.R84H | Q6IAA8 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LAMTOR1 | SNV | Missense_Mutation | rs564426310 | c.136N>A | p.Ala46Thr | p.A46T | Q6IAA8 | protein_coding | tolerated(0.72) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LAMTOR1 | SNV | Missense_Mutation | c.272N>A | p.Arg91His | p.R91H | Q6IAA8 | protein_coding | tolerated(0.07) | benign(0.018) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| LAMTOR1 | SNV | Missense_Mutation | rs564426310 | c.136G>A | p.Ala46Thr | p.A46T | Q6IAA8 | protein_coding | tolerated(0.72) | benign(0) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |